Edition:
India

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

24.30USD
15 Dec 2017
Change (% chg)

$-1.01 (-3.99%)
Prev Close
$25.31
Open
$25.26
Day's High
$25.58
Day's Low
$24.06
Volume
354,732
Avg. Vol
24,762
52-wk High
$28.95
52-wk Low
$17.42

Summary

Name Age Since Current Position

Frederick Beddingfield

51 President, Chief Executive Officer, Director

Richard Peterson

49 2017 Chief Financial Officer

Majed Kheir

Vice President - Operations

Susan Lundeen

Vice President - Human Resources

Robert More

2016 Director

Biographies

Name Description

Frederick Beddingfield

Dr. Frederick C. Beddingfield III, M.D., Ph.D., is a President, Chief Executive Officer, Director of the Company. He is also a board-certified dermatologist and dermatologic surgeon. Dr. Beddingfield served as Chief Medical Officer of Kythera Biopharmaceuticals, Inc. from March, 2013 until it was acquired by Allergan in October, 2015. Prior to his appointment at Kythera, he held the role of Vice President and Therapeutic Area Head, Dermatology and Aesthetics at Allergan, Inc. Dr. Beddingfield also served as Chief Medical Officer of Allergan Medical and led the development of premier products in the dermatology and aesthetics industry, including KYBELLA®, BOTOX® Cosmetic, JUVEDERM XC®, VOLUMA XC®, LATISSE®, and NATRELLE® Breast Implants, all market-leading aesthetic treatments in their respective categories. During his tenure at Allergan, Dr. Beddingfield also led programs in acne, rosacea, scarring, hyperhidrosis, and hair loss. Dr. Beddingfield earned an MD degree with Honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies, while simultaneously completing his Dermatology residency and Dermatologic Surgery fellowship at UCLA in the STAR program. He was the recipient of the Elle Genius Award in 2009. Currently, Dr. Beddingfield is a Clinical Associate Professor of Medicine/Dermatology at the UCLA School of Medicine where he has been on the faculty teaching and seeing patients since 2003. He serves on the Board of Directors of Advancing Innovation in Dermatology and is a founder of the Dermatology Summit and Dermatology Entrepreneurship Conferences. He also serves on the Board of Directors for Camp Wonder, a camp for children with severe skin diseases as well as the Board of Directors of Cytrellis, Inc. an aesthetic medical device company.

Richard Peterson

Mr. Richard D. Peterson is a Chief Financial Officer of the Company. Mr. Peterson has over two decades of experience in the areas of executive management, corporate governance, finance and accounting. He most recently served as the Chief Financial Officer of Novan, Inc., from September 2015 to March 2017. He served as Chief Financial Officer, Executive Vice President and Treasurer of Medicis Pharmaceutical Corporation from April 2008 to December 2012 and various other senior finance positions from 1995-2008. Prior to joining Medicis, Mr. Peterson was a Senior Financial Auditor with PricewaterhouseCoopers. Mr. Peterson has been an Independent Director and audit committee chair at Universal Insurance Holdings Inc. since 2014.

Majed Kheir

Mr. Majed Kheir is a Vice President - Operations of the company. Kheir served as Executive Director Supply Chain and Planning at Kythera Biopharmaceuticals, Inc. from 2012 to late 2015. Mr. Kheir also served as Kythera’s Head of Integration during Allergan’s $2.1B acquisition. Prior to that, Mr. Kheir held various positions at Amgen Inc., a biotechnology company. From 2009 to 2012, Mr. Kheir led corporate initiatives as Director Operations Strategic Planning, including optimization of Amgen’s manufacturing network, reduction in supply risk, global product allocation strategy and pipeline supply strategies. In 2010, Mr. Kheir established the business case that led to Amgen’s acquisition of its Ireland manufacturing facility from Pfizer, and served in a leadership role during the acquisition and site integration. From 2003 to 2009, Mr. Kheir held both strategic and technical roles in Drug Product Process Development and Strategic Resource Planning. Prior to Amgen, Mr. Kheir held various packaging engineering positions of increasing responsibility at Kimberly-Clark Corp. Mr. Kheir received an MBA from the Anderson School of Management at the University of California, Los Angeles and a BS in Packaging from Michigan State University.

Susan Lundeen

Ms. Susan Lundeen is a Vice President - Human Resources of the Company. from October, 2006 until it was acquired by Allergan in October, 2015. Ms. Lundeen was responsible for designing people systems, decision-making processes and cultural initiatives to grow the company from a privately held, start-up to a public, commercial organization. From September 2005 to June 2007, Ms. Lundeen was Vice President of Human Resources and Administration at Activus Healthcare Solutions, Inc., a healthcare distribution company. Prior to that experience, from February 1993 to September 2005, Ms. Lundeen held various positions at Amgen and ultimately served as Senior Director of Human Resources responsible for Strategic Sourcing and Staffing. Ms. Lundeen received a BA in Psychology and Business Administration from California Lutheran University and currently chairs the Board of Regents for California Lutheran University.

Robert More

Mr. Robert More is a Director of the Company. More joined Sienna Labs as Chairman of the Board in May 2013. He brings over 20 years of life sciences investing experience. Most recently, he was a Senior Advisor for Bill and Melinda Gates Foundation and led the “Global Health Venture Initiative.” Previously, he was a General Partner with Frazier Healthcare Ventures and Domain Associates. Bob managed successful investments in and served on the boards of ESP Pharma (acquired by Protein Design Labs, Inc.), Proxima Therapeutics (acquired by Cytyc Corporation), NovaCardia (acquired by Merck), Esprit Pharma (acquired by Allergan), IntraLase (acquired by Advanced Medical Optics, Inc.), Oceana Therapeutics (acquired by Salix Pharmaceuticals), Achaogen (NASDAQ: AKAO), Neothetics, (NASDAQ: NEOT) and Glaukos Corporation (NYSE: GLKS). Bob was also an investor in Clovis Pharmaceuticals, Affinivax, and Sienna Labs. He was a founding Board member of the Kauffman Fellows Program and serves on the boards of One Revolution and The Foundation for Innovative New Diagnostics (FIND). He received his B.A. from Middlebury College and an M.B.A. from the Darden School of Business Administration at the University of Virginia.

Basic Compensation

Options Compensation